Vera Therapeutics Q3 2026 EPS Tops Estimates at -$1.30, but Revenue Misses at $3.1M
Revenue of $3.1M vs. $3.4M expected and adjusted EPS of -$1.30 vs. -$1.62.
Vera Therapeutics (VERA) posted mixed third-quarter 2026 results, with adjusted EPS above the estimate and revenue below it. Revenue was $3.1 million below the $3.4 million estimate, and adjusted EPS was -$1.30, down 3.2% from a year earlier, above the -$1.62 estimate.
Shares rose 3.5% in after-hours trading as of 4:22 p.m. ET, to $31.19 from a $30.14 close.
Q3 2026 scorecard
| Parameters | Expected | Actual | Beat/Miss |
|---|---|---|---|
| Adjusted EPS | -$1.62 | -$1.30 | Beat by 20% |
| Revenue | $3.4M | $3.1M | Miss by 9.2% |
By our calculation, revenue was $314 thousand below the estimate and adjusted EPS was $0.32 above it.
Track record
- EPS record. Adjusted EPS beat the estimate in 3 of the last 8 reports, including this one.
What to watch
- Next-quarter estimates. Consensus calls for EPS of -$1.47 and revenue of $16.9 million next quarter, based on 6 analysts.
- Estimate record. Whether Vera Therapeutics returns to beating EPS estimates, which it did in 3 of its last 8 reports.
- Share reaction. How shares trade in the next regular session after the 3.5% gain in after-hours trading.
- Related coverage. See our reports on Helios, Ameren, Chesapeake Utilities and Concentra Group Holdings Parent.
Sources: Results are from Vera Therapeutics's Nov. 5, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from Vera Therapeutics's earlier quarterly reports. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.
Readers also read
Helios Beats Q3 2026 Estimates as Revenue Rises 4.3% to $229.7M
EarningsAmeren Beats Q3 2026 Estimates as Revenue Rises 6.8% to $2.88B
EarningsChesapeake Utilities Q3 2026 Revenue Tops Estimates at $195.8M, but EPS Misses at $0.89
EarningsConcentra Group Holdings Parent Beats Q3 2026 Estimates as Revenue Rises 8.6% to $622.1M
MarketCatalyst is not a registered investment advisor and does not manage client assets. Content on this platform is provided for informational and educational purposes only. It is not investment advice, and MarketCatalyst is not a stock-picking or trade-alert service. Trading stocks and options involves risk, including the possible loss of principal. Consider your own goals, time horizon, and risk tolerance, and consult a qualified financial advisor before making any investment decision.